We are analyzing https://link.springer.com/article/10.1007/s002800100294.

Title:
Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells | Cancer Chemotherapy and Pharmacology
Description:
Purpose: During tumorigenesis several cancer-related genes can be silenced by aberrant methylation. In many cases these silenced genes can be reactivated by exposure to the DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-AZA-CdR). Histone acetylation also plays a role in the control of expression of some genes. The aim of this study was to determine the antineoplastic activities of 5-AZA-CdR and trichostatin A (TSA), either administered alone or in combination, in MDA-MB-231 breast carcinoma cells. The effects of these drugs (alone and in combination) on the expression of the tumor suppressor gene, retinoic acid receptor (RARβ) and of the estrogen receptor α gene (ERα), whose expression is lost in the cell line used in the study, were also investigated. Methods: MDA-MB-231 cells were treated with 5-AZA-CdR and TSA and the antitumor activity of these drugs was determined by clonogenic assay. Total RNA was extracted from the treated cells and RT-PCR was used to determine the effect of the treatment on the expression of RARβ and ERα. Methylation-sensitive PCR analysis was used to confirm that lack of expression of both genes was due to hypermethylation of their promoter regions. A single nucleotide primer extension assay was also used to quantify the reduction in DNA methylation following drug treatment. Results: Both 5-AZA-CdR and TSA alone showed significant antineoplastic activity. The combination of the two drugs was synergistic with respect to MDA-MB-231 cell kill. 5-AZA-CdR alone weakly activated the expression of both RARβ and ERα. TSA alone only activated RARβ, but not ERα. The combination of these agents appeared to produce a greater activation of both genes. Conclusions: The interesting interaction between 5-AZA-CdR and TSA in both cell kill and cancer-related gene reactivation provides a rationale for the use of inhibitors of DNA methylation and histone deacetylation in combination for the chemotherapy of breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

article, receptor, cancer, expression, breast, methylation, genes, cells, azacdr, access, privacy, cookies, content, estrogen, dna, tsa, combination, information, publish, search, antineoplastic, azadeoxycytidine, histone, retinoic, acid, rarβ, erα, analysis, data, log, journal, research, chemotherapy, inhibitor, effect, carcinoma, july, bovenzi, momparler, mdamb, drugs, gene, cell, treatment, open, discover, springer, optional, personal, parties,

Topics {✒️}

methylation-sensitive pcr analysis month download article/chapter cancer-related gene reactivation estrogen-independent aggressive phenotype dna methylation inhibitor retinoic acid receptor tumor suppressor gene breast carcinoma cells mda-mb-231 cell kill dna methylation article cancer chemotherapy estrogen receptor alpha cancer-related genes mda-mb-231 cells related subjects privacy choices/manage cookies full article pdf breast cancer drug treatment université de montréal aberrant methylation article bovenzi european economic area july 2001 volume 48 chronic oxidative stress hôpital ste-justine 3175 côte ste-catherine conditions privacy policy usage analysis check access instant access histone deacetylase inhibitor accepting optional cookies québec h3t 1c5 main content log journal finder publish article log epigenetic inactivation article cite antineoplastic action treated cells privacy policy personal data cell kill information clonogenic assay books a 5-aza-2′-deoxycytidine optional cookies manage preferences

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells
         description: Purpose: During tumorigenesis several cancer-related genes can be silenced by aberrant methylation. In many cases these silenced genes can be reactivated by exposure to the DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-AZA-CdR). Histone acetylation also plays a role in the control of expression of some genes. The aim of this study was to determine the antineoplastic activities of 5-AZA-CdR and trichostatin A (TSA), either administered alone or in combination, in MDA-MB-231 breast carcinoma cells. The effects of these drugs (alone and in combination) on the expression of the tumor suppressor gene, retinoic acid receptor (RARβ) and of the estrogen receptor α gene (ERα), whose expression is lost in the cell line used in the study, were also investigated. Methods: MDA-MB-231 cells were treated with 5-AZA-CdR and TSA and the antitumor activity of these drugs was determined by clonogenic assay. Total RNA was extracted from the treated cells and RT-PCR was used to determine the effect of the treatment on the expression of RARβ and ERα. Methylation-sensitive PCR analysis was used to confirm that lack of expression of both genes was due to hypermethylation of their promoter regions. A single nucleotide primer extension assay was also used to quantify the reduction in DNA methylation following drug treatment. Results: Both 5-AZA-CdR and TSA alone showed significant antineoplastic activity. The combination of the two drugs was synergistic with respect to MDA-MB-231 cell kill. 5-AZA-CdR alone weakly activated the expression of both RARβ and ERα. TSA alone only activated RARβ, but not ERα. The combination of these agents appeared to produce a greater activation of both genes. Conclusions: The interesting interaction between 5-AZA-CdR and TSA in both cell kill and cancer-related gene reactivation provides a rationale for the use of inhibitors of DNA methylation and histone deacetylation in combination for the chemotherapy of breast cancer.
         datePublished:
         dateModified:
         pageStart:71
         pageEnd:76
         sameAs:https://doi.org/10.1007/s002800100294
         keywords:
            Breast cancer 5-Aza-2′-deoxycytidine Trichostatin A Retinoic acid receptor β Estrogen receptor α DNA methylation
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:48
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Veronica Bovenzi
               affiliation:
                     name:Département de pharmacologie, Université de Montréal, Québec, Canada
                     address:
                        name:Département de pharmacologie, Université de Montréal, Québec, Canada,
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Richard L. Momparler
               affiliation:
                     name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada
                     address:
                        name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada,
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells
      description: Purpose: During tumorigenesis several cancer-related genes can be silenced by aberrant methylation. In many cases these silenced genes can be reactivated by exposure to the DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-AZA-CdR). Histone acetylation also plays a role in the control of expression of some genes. The aim of this study was to determine the antineoplastic activities of 5-AZA-CdR and trichostatin A (TSA), either administered alone or in combination, in MDA-MB-231 breast carcinoma cells. The effects of these drugs (alone and in combination) on the expression of the tumor suppressor gene, retinoic acid receptor (RARβ) and of the estrogen receptor α gene (ERα), whose expression is lost in the cell line used in the study, were also investigated. Methods: MDA-MB-231 cells were treated with 5-AZA-CdR and TSA and the antitumor activity of these drugs was determined by clonogenic assay. Total RNA was extracted from the treated cells and RT-PCR was used to determine the effect of the treatment on the expression of RARβ and ERα. Methylation-sensitive PCR analysis was used to confirm that lack of expression of both genes was due to hypermethylation of their promoter regions. A single nucleotide primer extension assay was also used to quantify the reduction in DNA methylation following drug treatment. Results: Both 5-AZA-CdR and TSA alone showed significant antineoplastic activity. The combination of the two drugs was synergistic with respect to MDA-MB-231 cell kill. 5-AZA-CdR alone weakly activated the expression of both RARβ and ERα. TSA alone only activated RARβ, but not ERα. The combination of these agents appeared to produce a greater activation of both genes. Conclusions: The interesting interaction between 5-AZA-CdR and TSA in both cell kill and cancer-related gene reactivation provides a rationale for the use of inhibitors of DNA methylation and histone deacetylation in combination for the chemotherapy of breast cancer.
      datePublished:
      dateModified:
      pageStart:71
      pageEnd:76
      sameAs:https://doi.org/10.1007/s002800100294
      keywords:
         Breast cancer 5-Aza-2′-deoxycytidine Trichostatin A Retinoic acid receptor β Estrogen receptor α DNA methylation
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:48
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Veronica Bovenzi
            affiliation:
                  name:Département de pharmacologie, Université de Montréal, Québec, Canada
                  address:
                     name:Département de pharmacologie, Université de Montréal, Québec, Canada,
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Richard L. Momparler
            affiliation:
                  name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada
                  address:
                     name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada,
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:48
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Département de pharmacologie, Université de Montréal, Québec, Canada
      address:
         name:Département de pharmacologie, Université de Montréal, Québec, Canada,
         type:PostalAddress
      name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada
      address:
         name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada,
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Veronica Bovenzi
      affiliation:
            name:Département de pharmacologie, Université de Montréal, Québec, Canada
            address:
               name:Département de pharmacologie, Université de Montréal, Québec, Canada,
               type:PostalAddress
            type:Organization
      name:Richard L. Momparler
      affiliation:
            name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada
            address:
               name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada,
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Département de pharmacologie, Université de Montréal, Québec, Canada,
      name:Centre de recherche pédiatrique, Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, Canada,
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(27)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.73s.

LINK . SPRINGER . COM {}